Key Points
- David Malcom Rodman sold 2,170 shares of Mineralys on April 9 at an average price of $27.38 for $59,414.60, and the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
- The sale is part of a string of recent insider dispositions that reduced Rodman's ownership by 2.77% to 76,140 shares, valued at about $2.08 million, after multiple earlier sales totaling hundreds of thousands of dollars.
- Mineralys has a market cap of roughly $2.24 billion, recently beat quarterly EPS expectations (‑$0.40 vs. ‑$0.57), and holds a consensus analyst rating of "Moderate Buy" with an average price target near $49.14.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 2,170 shares of the firm's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $27.38, for a total value of $59,414.60. Following the completion of the sale, the insider directly owned 76,140 shares of the company's stock, valued at $2,084,713.20. This represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Malcom Rodman also recently made the following trade(s):
- On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total value of $173,744.76.
- On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total value of $369,163.08.
- On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total value of $58,269.64.
- On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total value of $11,505.03.
- On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total value of $184,057.51.
- On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total value of $385,669.20.
- On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total value of $65,585.91.
- On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.10, for a total value of $13,353.60.
- On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total value of $370,677.87.
- On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total value of $252,469.75.
Mineralys Therapeutics Stock Performance
Shares of NASDAQ MLYS opened at $27.16 on Tuesday. The stock has a market cap of $2.24 billion, a PE ratio of -11.46 and a beta of 0.69. Mineralys Therapeutics, Inc. has a fifty-two week low of $12.59 and a fifty-two week high of $47.65. The stock has a fifty day moving average of $27.35 and a 200-day moving average of $34.48.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. On average, sell-side analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on MLYS. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Jefferies Financial Group reiterated a "hold" rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research report on Friday, March 13th. HC Wainwright set a $56.00 price objective on Mineralys Therapeutics and gave the company a "buy" rating in a research note on Tuesday, March 10th. Wall Street Zen raised Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, March 15th. Finally, Stifel Nicolaus lifted their price objective on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research note on Friday, December 19th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $49.14.
View Our Latest Analysis on Mineralys Therapeutics
Institutional Investors Weigh In On Mineralys Therapeutics
Several large investors have recently added to or reduced their stakes in MLYS. Navalign LLC bought a new stake in Mineralys Therapeutics during the fourth quarter valued at $33,000. Smartleaf Asset Management LLC boosted its stake in Mineralys Therapeutics by 198.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock valued at $40,000 after buying an additional 676 shares during the period. Royal Bank of Canada boosted its stake in Mineralys Therapeutics by 262.3% during the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock valued at $56,000 after buying an additional 1,107 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in Mineralys Therapeutics by 1,845.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company's stock valued at $76,000 after buying an additional 1,993 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in Mineralys Therapeutics by 14,091.3% during the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company's stock valued at $124,000 after buying an additional 3,241 shares during the period. Institutional investors own 84.46% of the company's stock.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
